SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Dogecoin is an open-source digital currency based on the "Doge" meme that functions as a peer-to-peer medium for fast payments and digital tipping. Unlike projects backed by corporate entities, its value is driven by a global community, and the project is managed by a decentralized group of volunteers and the non-profit Dogecoin Foundation rather than a formal company.  Originally created in 2013 by software engineers Billy Markus and Jackson Palmer as a market parody, the project held no public sale or venture capital rounds. The network operates as a fork of LuckyCoin, which itself was a fork of Litecoin, using a proof of work consensus mechanism. It employs the Scrypt algorithm to ensure the mining process remains fast and efficient, with new blocks processed every 60 seconds. A unique technical feature is its use of merged mining, allowing miners to secure Dogecoin simultaneously with other Scrypt-based networks like Litecoin.  To keep transaction fees low and the network running indefinitely, Dogecoin features an uncapped supply where new coins are added forever. In a major regulatory milestone in March 2026, a joint SEC and CFTC framework officially classified Dogecoin as a digital commodity, placing it in the same asset category as gold or oil.

Dogecoin

Dogecoin is facing heightened volatility and intense debate among investors as the community remains sharply divided over the coin's future utility and market position. While some participants are actively accumulating during price dips, others are vocalizing deep skepticism, framing the asset as a speculative gamble tied to shifting market sentiment.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is trending as investors bet on a potential buyout, fueled by bullish analyst price target hikes and excitement over the expansion of its core drug, Briumvi, into new indications like schizophrenia. Community discussion is heavily focused on the company's strong commercial growth, low float dynamics, and the belief that a strategic acquisition could happen rapidly as the stock hits new highs.

Liquidia Corp. operates as a holding company which engages through its subsidiary in developing and commercializing biopharmaceutical products and novel products development used in PRINT technology to transform the lives of patients. The company was founded in June 2004 and is headquartered in Morrisville, NC.

Liquidia Corp

Liquidia Corp is currently in the spotlight as investors weigh its robust commercial performance, characterized by rapid Yutrepia adoption, against the lingering uncertainty of a high-stakes patent litigation ruling. Community discourse is heavily focused on the stock's resilient breakout momentum despite broader market volatility, with ongoing debates comparing its growth trajectory and management execution favorably against other sector players.

Legend Biotech Corp. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, manufacturing, and commercialization of novel therapies for oncology and other indications. The firm develops advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell, gamma-delta T cell and natural killer cell-based immunotherapy. It operates through the following geographical segments: United States of America, China, and Other. The company was founded in 2014 and is headquartered in Somerset, NJ.

Legend Biotech Corp - ADR

Legend Biotech

Legend Biotech is trending due to significant investor debate over its long-term standalone viability versus an imminent buyout following reports of competitive pressure in the multiple myeloma space. The community is actively weighing the company's strong commercial growth and pipeline potential against analyst concerns over rising competition and the strategic implications of its partnership with Johnson & Johnson.

Shutterstock, Inc. engages in the provision of a global creative platform. The company offers data, distribution, and services. Its contents include images, footage, music, three dimensional (3D) models, and generative artificial intelligence. The company was founded by Jonathan Evan Oringer in 2003 and is headquartered in New York, NY.

Shutterstock Inc

Investors are closely monitoring the potential for a dividend cut or share buyback program as a primary catalyst for the stock amid ongoing volatility and a recent merger termination. The community is divided between those viewing the company as deeply undervalued due to its proprietary image library and data licensing potential, and others concerned about the long-term impact of generative AI competition on its core business model.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

CRISPR Therapeutics is facing downward pressure following a convertible note offering, while investors remain focused on key pipeline readouts expected later in 2026 as the primary catalysts for long-term valuation. Community sentiment is deeply polarized, with many retail holders expressing frustration over prolonged range-bound price action and limited near-term news flow, while others continue to debate the potential for a strategic buyout or a significant reversal driven by upcoming clinical data.

Vanguard Index Funds - Vanguard S&P 500 ETF

Vanguard S&P 500 ETF

Vanguard S&P 500 ETF (VOO) is trending as investors weigh persistent geopolitical risks in the Middle East against the index's record-breaking asset growth. The community remains deeply divided, with many debating whether to maintain a "buy and chill" strategy during market volatility or to shift toward hedging amid concerns over U.S. labor data and potential interest rate adjustments.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. It operates through the Steelmaking and Other Businesses segments. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs is currently trending as investors weigh strong domestic steel pricing and government contracts for electrical steel against frustration with stagnant price action and perceived market manipulation. The community remains deeply divided, with many debating the impact of upcoming earnings, the long-rumored POSCO partnership, and skepticism toward current management's ability to drive sustained share price growth.

TOSHI

TOSHI is drawing significant community attention as investors speculate on potential ecosystem developments, including AI-driven utility and broader Base network integration. Despite recent price volatility, the community remains actively focused on accumulation, citing historical recovery patterns and anticipation of future catalysts to fuel a potential trend reversal.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as investors await the July 29th Advisory Committee meeting for Deramiocel, with community sentiment split between concerns over a recent patent lawsuit filed by Mesoblast and high expectations for an approval that could trigger a significant short squeeze. Despite recent volatility and negative price action, long-term investors are focused on the drug's positive clinical data and the company's recent expansion of its manufacturing footprint as bullish indicators for a successful commercial launch.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease

AN2 Therapeutics, Inc. (Nasdaq: ANTX) a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced positive results from two studies evaluating the Companys oral CPSF3 inhibitor, AN2-502998, for the treatment of...

AN2 Therapeutics to Present at 2026 Jefferies Global Healthcare Conference

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company advancing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO will present at the 2026 Jefferies Global Healthcare Conference on June...

AN2 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business and Scientific Highlights

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today reported financial results for the first quarter ended March 31, 2026. This was an...

AN2 Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company advancing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder...

Anthem (NASDAQ:ANTX) Raised to "Hold" at Wall Street Zen

Wall Street Zen upgraded Anthem from a "sell" rating to a "hold" rating in a research report on Sunday...

Anthem (NASDAQ:ANTX) Downgraded to "Sell" Rating by Wall Street Zen

Wall Street Zen downgraded Anthem from a "hold" rating to a "sell" rating in a research report on Saturday...

Anthem (NASDAQ:ANTX) Upgraded by Wall Street Zen to "Hold" Rating

Wall Street Zen raised shares of Anthem to a "hold" rating in a report on Saturday...

Anthem (NASDAQ:ANTX) Stock Price Up 1.2% - Still a Buy?

Anthem (NASDAQ:ANTX) Shares Up 1.2% - Still a Buy...

AN2 Therapeutics Announces Initiation of Phase 2 Investigator-Initiated Clinical Trial of Epetraborole for Mycobacterium abscessus Complex Lung Disease

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced the initiation of a Phase 2 investigator-initiated clinical trial evaluating the safety, efficacy, and...

AN2 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business and Scientific Highlights

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry...

AN2 Therapeutics, Inc. operates as a global health biopharmaceutical company. The firm focuses on modern biomedical and drug development to provide transformational medicines for patients suffering from infectious diseases. The company was founded by Eric Easom, George Harrison Talbot, Joseph S. Zakrzewski and Michael R.K. Alley in 2017 and is headquartered in Menlo Park, CA.

AN2 Therapeutics Inc

ANTX Stock Records Biggest Ever Single Day Gain, Surges 500% Over Past Four Sessions – What Triggered This Smashing Rally?

Equity

Neutral Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

The S&P 500 ($SPY) is pacing for a losing week as a semiconductor ($SMH) sell-off has dragged the market lower amid growing doubts about AI spending. What do you think the index's return will look like next week? Vote and explain your reasoning in the comments.

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	-$0.23	--	--	N/A
Q1 '26	-$0.23	-$0.29	-26.09%	MISSED
Q4 '25	-$0.24	-$0.29	-20.83%	MISSED
Q3 '25	-$0.22	-$0.31	-40.91%	MISSED
Q2 '25	-$0.34	-$0.21	37.31%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

ANTXAN2 Therapeutics Inc

Latest Earnings Results: Q1 '26

Historical Earnings

Latest ANTX News